High level of miR-196b at newly diagnosed pediatric acute myeloid leukemia predicts a poor outcome

Differential expression of microRNAs (miRNAs) has been implicated in leukemogenesis. We investigate the expression pattern of miR-196b. Using quantitative real-time PCR (qRT-PCR), we detected the expression of miR-196b and its correlated genes (SMC1A/MLH1) in initial pediatric AML. A significant association was observed between overexpression of miR-196b and inferior overall survival of pediatric AML (Log Rank P<0.0001). AML M4/5 subtype, high white blood cell (WBC) count at presentation, MLL rearrangement, or FLT3-ITD mutation at diagnosis and non-remission group after the first induction chemotherapy possessed higher miR-196b expression. Furthermore, a positive relationship was found between the expression of miR-196b and SMC1A/MLH1 (Spearman's r=0.37 and 0.44, P=0.001 and <0.0001, respectively). Taken together, these findings suggest that differentially high expression of miR-196b in diagnostic marrow samples of pediatric AML is associated with unfavorable outcome, and miR-196b potentially can be a novel biomarker for the diagnosis, prognosis and treatment in pediatric AML.

[1]  M. Moore,et al.  AHNS Series – Do you know your guidelines?: Assessment and management of malnutrition in patients with head and neck cancer: Review of the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines) , 2018, Head & neck.

[2]  Jiajia Chen,et al.  MicroRNA biomarker identification for pediatric acute myeloid leukemia based on a novel bioinformatics model , 2015, Oncotarget.

[3]  Xuan Zhou,et al.  MicroRNA-196b promotes cell proliferation and suppress cell differentiation in vitro. , 2015, Biochemical and biophysical research communications.

[4]  F. Locatelli,et al.  Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations , 2014, Leukemia.

[5]  J. Esteve,et al.  MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia , 2014, Leukemia.

[6]  Bairong Shen,et al.  Identification of candidate miRNA biomarkers from miRNA regulatory network with application to prostate cancer , 2014, Journal of Translational Medicine.

[7]  P. Kearns,et al.  Novel therapies for children with acute myeloid leukaemia , 2013, Leukemia.

[8]  G. Inghirami,et al.  Core binding factor acute myeloid leukaemia and c-KIT mutations. , 2013, Oncology reports.

[9]  Jing Zheng,et al.  Knocking down SMC1A inhibits growth and leads to G2/M arrest in human glioma cells. , 2013, International journal of clinical and experimental pathology.

[10]  D. Johnston,et al.  Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. , 2012, Blood.

[11]  R. Pieters,et al.  Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia , 2012, Pediatric blood & cancer.

[12]  S. Lowe,et al.  The microcosmos of cancer , 2012, Nature.

[13]  C. Pui,et al.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Thiel,et al.  The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia. , 2011, Leukemia research.

[15]  S. Koschmieder,et al.  Low SMC1A protein expression predicts poor survival in acute myeloid leukemia. , 2010, Oncology reports.

[16]  I. Bernstein,et al.  Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. , 2010, Blood.

[17]  Jianjun Chen,et al.  MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. , 2010, Blood cells, molecules & diseases.

[18]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[19]  J. Rowley,et al.  Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. , 2009, Blood.

[20]  Lin Li,et al.  [Research update on pharmacogenomics in acute leukemia - review]. , 2008, Zhongguo shi yan xue ye xue za zhi.

[21]  Liya Gu,et al.  Evidence That a Mutation in the MLH1 3′-Untranslated Region Confers a Mutator Phenotype and Mismatch Repair Deficiency in Patients with Relapsed Leukemia* , 2008, Journal of Biological Chemistry.

[22]  D. Liang,et al.  Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples , 2008, Leukemia.

[23]  T. Golub,et al.  MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia , 2007, Proceedings of the National Academy of Sciences.

[24]  K. Basso,et al.  Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: Identification of candidate amplified and overexpressed genes , 2007, Genes, chromosomes & cancer.

[25]  George P Cobb,et al.  microRNAs as oncogenes and tumor suppressors. , 2007, Developmental biology.

[26]  H. Dombret,et al.  Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) , 2006, Leukemia.

[27]  Y. Hayashi,et al.  KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. , 2006, Blood.

[28]  [Suggestion of diagnosis and treatment of acute myelocytic leukemia in childhood]. , 2006, Zhonghua er ke za zhi = Chinese journal of pediatrics.

[29]  U. Creutzig,et al.  Pediatric acute myeloid leukemia: international progress and future directions , 2005, Leukemia.

[30]  R. Arceci,et al.  Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891 , 2005, Leukemia.

[31]  M. Felice,et al.  Treatment strategy and long-term results in pediatric patients treated in two consecutive AML-GATLA trials , 2005, Leukemia.

[32]  Chang-Zheng Chen,et al.  MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.

[33]  S. Meshinchi,et al.  Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia , 2005, Leukemia.

[34]  R. Verhaak,et al.  Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.

[35]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[36]  T. Tuschl,et al.  Identification of Novel Genes Coding for Small Expressed RNAs , 2001, Science.